North Tide Capital LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
North Tide Capital LLC
CRD #157585
SEC #801-73783
CIK #0001557543
AUM
Employees 8 (100% Investors, 0% Brokers)
Fees
Minimum
Phone617-449-3120
Address500 Boylston Street
Boston, MA 02116
Source [IAPD] [EDGAR] [Website]
Total AUM ($B)
3.02.41.81.20.60.02010201520212027
Fees and Compensation — Form ADV Part 2A (3/31/2017) [Brochure]
ITEM 5 – FEES AND COMPENSATION
Management Fee and Performance Allocation

North Tide is compensated by Main Fund Investors in the form of a monthly management fee (the
“Management Fee”) paid by the Master Fund. The Management Fee will be payable in arrears
(regardless of a client’s profits) and will be deducted in determining the net profit or net loss of the U.S.
Fund and the Offshore Fund. The Management Fee is calculated based on the balance in each Main Fund
Investor’s capital account or the net asset value of each Main Fund Investor’s series of shares, as
applicable and equals 0.125% per month (approximately 1.5% annualized), at the end of each month
(computed prior to the payment or accrual of any Performance Allocation). The Management Fee is
prorated for partial months.

In connection with the investment management services North Tide provides, it will bear all of its own
normal and recurring operating expenses and overhead costs, except that research and research-related
expenses may be paid for through the permitted use of “soft dollars” (as described in Item 12 - Brokerage
Practices). The Management Fee may exceed the expenses borne by North Tide on behalf of the Main
Funds.

Generally at the end of each fiscal year, the General Partners will have reallocated to their capital
accounts in the Master Funds (after reduction for the Management Fee and other expenses and fees
incurred by the U.S. Funds and the Offshore Funds) a Performance Allocation equal to 20% of the excess
net profits over net losses attributable to each Fund Investor’s capital account or series of shares (and
reflected in corresponding sub-accounts kept with respect to each such Fund Investor at the Master Funds
level) for such fiscal year, subject to a customary high-watermark described below. In the event a Fund
Investor is permitted or required to withdraw or redeem completely or partially from the U.S. Funds or
Offshore Funds other than at the end of the fiscal year, the Performance Allocation made at the Master
Funds level with respect to such Fund Investor for such year will be determined with respect to the
portion being withdrawn or redeemed through the applicable withdrawal date.

A memorandum loss recovery account (a “Loss Recovery Account”), sometimes called a “high-
watermark”, will be maintained with respect to each Fund Investor and will be increased by the aggregate
net losses, if any, allocated to such Fund Investor for such year and reduced (but not below zero) by any
net profits allocated to such Fund Investor for such year (before any Performance Allocation). The
General Partners (as applicable) will not be allocated any Performance Allocation with respect to a Fund
Investor until such Fund Investor has recovered any net losses allocated to its Loss Recovery Account.
The loss amount allocated to the Loss Recovery Account will be decreased pro rata to account for any
withdrawals or redemptions made prior to the end of a fiscal year.

The Management Fee and Performance Allocation may, in the sole discretion of North Tide or the
General Partners (as applicable) be waived, reduced, or rebated with respect to certain Fund Investors,
including affiliates of the General Partners or North Tide.

North Tide (or an affiliate) deducts applicable fees from Fund Investor assets invested in the Funds. Fund
Investors do not have the ability to choose to be billed directly for fees incurred.

North Tide also receives from the Account an asset based quarterly management fee and an annual
performance based fee, subject to a high-watermark similar to that described above, in the amounts set
forth in the agreement between North Tide and the Account investor.

Expenses

In addition to fees payable to North Tide, the Funds (and therefore Fund Investors) may pay a variety of
expenses related to each Fund’s investments and operations, including, without limitation, brokerage and
other transaction costs, clearing and settlement charges, trade break fees, consulting expenses, research
and due diligence expenses (including research related travel expenses), legal fees and other expenses in
connection with conducting due diligence and negotiating the terms of certain investments, custodial fees,
initial and variation margin, interest and commitment fees on debit balances or borrowings, stock
borrowing fees and proxy solicitation expenses, legal expenses, audit and tax preparation expenses,
accounting fees, costs of the administration of the Funds (including, but not limited to, fees and expenses
of an administrator and third party valuation services), the Management Fee, regulatory costs and
expenses (including filing and licensing fees), organizational expenses, premiums for liability insurance,
fees for risk management services, indemnification expenses, entity-level taxes, issue or transfer taxes,
costs of reporting to investors, costs of litigation or investigation involving Fund activities, any
extraordinary expenses, and other similar expenses related to the Funds.

A portion of the Funds’ expenses may be shared with other investment entities or accounts managed by
North Tide, the General Partners or their affiliates on an equitable basis.

Neither North Tide nor its supervised persons accept compensation, including sales charges or service
fees, from any person for the sale of securities or other investment products, including interests in the
Funds.
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2017) [Brochure]
ITEM 7 – TYPES OF CLIENTS
As previously described in Item 4, North Tide’s clients consist of the Funds and the Account. Investors
in the Funds and the Account consist of institutional investors and other sophisticated investors.

The minimum investment in the Funds is $1,000,000, which may be reduced by the General Partners of
the U.S. Funds or Board of Directors of the Offshore Funds, as applicable. Interests in the U.S. Funds
may only be purchased by investors that are “accredited investors,” as defined in Regulation D under the
Securities Act of 1933, as amended (the “Securities Act”), and “qualified purchasers,” as defined in
Section 2(a)(51)(A) of the Investment Company Act of 1940, as amended (the “1940 Act”). U.S.
investors in the Offshore Funds must also be “accredited investors” and “qualified purchasers.” Shares in
the Offshore Funds are typically offered to eligible investors that are not U.S. Persons or U.S. tax-exempt
entities.

The Account was established for a sophisticated institutional investor and involves a significant minimum
investment.
Sector Form 13F Holdings Value ($M)
McKesson Corp 76.8
Gilead Sciences Inc 40.5
Perrigo Co Ltd 25.4
Tenet Healthcare Corp 25.2
CVS Caremark Corp 20.3
Pacific Biosciences of California Inc 5.2
 
 
 
 
 
Holdings by Sector ($M)
1500120090060030002011201320152018
Type Form D Funds Date Sold AUM
PE Slack Tide-SPV 1 LLC 2026-06-17
HF NTC Special Opportunities I Master LP [2016-11-16] 20.6 M 84.6 M
Filed 2017-07-27 (D/A) · Exemption 506(b), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF North Tide Capital Master LP [2012-02-14] 25.1 M 1,261.8 M
Filed 2017-10-30 (D/A) · Exemption 506(b), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 0 0.0
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 7 1.6
By Discretionary
Discretionary 7 1.6
Non-Discretionary 0 0.0
Total 7 1.6
By Non-United States Persons
Non-United States Persons 0.0
United States Persons 1.6
Total 7 1.6
Form D Directors Role # Filings # Firms 2011 - 2026
Ronan Guilfoyle Director 358 108
Jennifer Collins Director 232 47
Kevin Phillip Director 193 39
Evan Burtton Director 83 34
Conan Laughlin Director, Executive Officer 4 2
North Tide Capital LLC Promoter 3 2
North Tide Capital GP II LLC Executive Officer 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001557543]
3 [0001557543]
4 [0001557543]
SC 13D [0001557543]
SC 13G [0001557543]
Form 13D/13G Filer Form 13D/13G Subject Filed
North Tide Capital LLC BioScrip Inc [2016-06-27]
North Tide Capital LLC Amedisys Inc [2015-11-16]
North Tide Capital LLC Amedisys Inc [2014-12-02]
North Tide Capital LLC Almost Family Inc [2014-12-02]
North Tide Capital LLC Kindred Healthcare Inc [2014-10-10]
North Tide Capital LLC Orthofix International N V [2014-04-04]
North Tide Capital LLC Select Medical Holdings Corp [2014-01-15]
North Tide Capital LLC Healthways Inc [2013-10-28]
North Tide Capital LLC Syneron Medical Ltd [2013-09-26]
North Tide Capital LLC Almost Family Inc [2013-09-09]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund, Private Equity
Form 3/4/5 Subject 2011 - 2026
North Tide Capital Master LP
Laughlin Conan
North Tide Capital LLC
Syneron Medical Ltd
Vivus Inc
NTC Special Opportunities I Master LP
Tivity Health Inc
Almost Family Inc
Amedisys Inc
Select Medical Holdings Corp
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Vivus Inc VVUS
Common Stock
2017-03-10 Sell 77,000 $1.17 90,090
Vivus Inc VVUS
Common Stock
2017-03-09 Sell 237,100 $1.20 284,520
Vivus Inc VVUS
Common Stock
2017-03-09 Sell 50,000 $1.25 62,500
Vivus Inc VVUS
Common Stock
2017-03-09 Sell 435,300 $1.21 526,713
Vivus Inc VVUS
Common Stock
2017-03-08 Sell 350,000 $1.05 367,500
Vivus Inc VVUS
Common Stock
2017-03-07 Sell 105,100 $1.07 112,457
Vivus Inc VVUS
Common Stock
2017-03-07 Sell 40,000 $1.08 43,200
Syneron Medical Ltd ELOS
Common Stock
2017-03-07 Sell 34,000 $10.30 350,200
Syneron Medical Ltd ELOS
Common Stock
2017-03-07 Sell 81,500 $10.28 837,820
Vivus Inc VVUS
Common Stock
2017-03-06 Sell 10,000 $1.10 11,000
Vivus Inc VVUS
Common Stock
2017-03-06 Sell 4,800 $1.10 5,280
Vivus Inc VVUS
Common Stock
2017-03-03 Sell 31,200 $1.11 34,632
Vivus Inc VVUS
Common Stock
2017-03-03 Sell 1,700 $1.11 1,887
Vivus Inc VVUS
Common Stock
2017-03-02 Sell 20,000 $1.13 22,600
Tivity Health Inc TVTY
Common Stock, $0.001 Par Value
2017-03-01 Sell 250,000 $28.30 7,075,000
Tivity Health Inc TVTY
Common Stock, $0.001 Par Value
2017-03-01 Sell 1,750,000 $28.30 49,525,000
Vivus Inc VVUS
Common Stock
2017-03-01 Sell 72,600 $1.14 82,764
Vivus Inc VVUS
Common Stock
2017-03-01 Sell 42,000 $1.13 47,460
Vivus Inc VVUS
Common Stock
2017-02-28 Sell 25,500 $1.12 28,560
Vivus Inc VVUS
Common Stock
2017-02-27 Sell 107,000 $1.13 120,910
showing 20 of 178 most recent transactions
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com